Competing Engagement of β-Arrestin Isoforms Balances IGF1R/p53 Signaling and Controls Melanoma Cell Chemotherapeutic Responsiveness

Researchers explored whether unbalancing this system downstream of insulin-like growth factor type 1 receptor (IGF1R) could enhance the response of melanoma cells to chemotherapy.